The redox homeostasis in the brain tissue is under the control of Nrf2, and there has been a growing interest in identifying natural or synthetic compounds (Figure 3) that are able to modify Nrf2 activity, for example, in MS, in which ROS/RNS have a recognized function [74]. The gene discussed is NFE2L2; the disease is myeloid sarcoma.